uniQure Faces Severe FDA Rebuke Amid Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy QURE?
Source: Globenewswire
- FDA Criticism: An FDA official labeled uniQure's lead gene therapy candidate AMT-130 as a 'failed therapy' during a media call, accusing the company of making 'distorted or manipulated comparisons' in clinical studies, which could undermine investor confidence in the company's future prospects.
- Ethical Controversy: The FDA dismissed uniQure's ethical concerns regarding sham surgeries, clarifying that it did not request 'drilling holes' but rather 'one to three nicks in the scalp' under minimal anesthesia, potentially damaging the company's reputation in clinical trials.
- Legal Action: uniQure is facing a securities class action lawsuit alleging that it failed to disclose the lack of regulatory consensus with the FDA during the Class Period from September 24 to October 31, 2025, leading to a 49% stock drop on November 3, which resulted in significant investor losses.
- Critical Deadline: Investors must apply to be Lead Plaintiff by April 13, 2026, highlighting the legal and regulatory pressures on the company that may impact its future financing and market performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QURE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QURE
Wall Street analysts forecast QURE stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 15.180
Low
33.00
Averages
49.88
High
70.00
Current: 15.180
Low
33.00
Averages
49.88
High
70.00
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
uniQure Faces Severe FDA Rebuke Amid Class Action Lawsuit
- FDA Rebuke: An FDA official publicly labeled uniQure's lead gene therapy candidate AMT-130 as a 'failed therapy,' accusing the company of conducting a 'distorted or manipulated comparison' in clinical studies, which could undermine investor confidence in the company's future prospects.
- Surgery Requirement Controversy: The FDA dismissed uniQure's ethical concerns regarding sham surgeries, clarifying that it did not request 'drilling holes' but rather 'one to three nicks in the scalp' under minimal anesthesia, potentially impacting the design and execution of the company's clinical trials.
- Legal Action Update: The securities class action against uniQure alleges that the company failed to disclose that the FDA had not approved the use of the ENROLL-HD external historical data set as a primary control for AMT-130, a lack of disclosure that may have led to significant investor losses when the stock price fell.
- Critical Deadline: Investors must apply to be Lead Plaintiff by April 13, 2026, or risk losing the opportunity to seek compensation in the lawsuit, heightening the urgency for affected shareholders to act promptly.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: uniQure N.V. (NASDAQ: QURE) is facing a class action lawsuit for securities fraud, alleging significant misstatements and omissions regarding its Huntington's disease gene therapy drug during the class period from September 24 to October 31, 2025, potentially leading to substantial investor losses.
- Stock Price Plunge: Following the revelation on November 3, 2025, that the FDA no longer accepted the data from uniQure's AMT-130 drug for BLA submission, the stock price plummeted by $33.40, or over 49%, from a closing price of $67.69 on October 31 to $34.29, severely impacting investor confidence.
- Investor Action: Affected investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP by April 13, 2026, to seek lead plaintiff status in the class action, highlighting investor concerns regarding corporate governance and transparency.
- Law Firm Background: Kessler Topaz Meltzer & Check, LLP is a leading law firm specializing in securities fraud class actions, having recovered over $25 billion for clients and represented major institutional investors, showcasing its significant influence and expertise in the securities litigation field.
See More
uniQure Faces Securities Class Action Lawsuit
- Lawsuit Deadline: Investors must file lead plaintiff applications by April 13, 2026, to participate in the securities class action against uniQure N.V. if they purchased shares between September 24 and October 31, 2025.
- Legal Allegations: uniQure and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which resulted in significant investor losses.
- Stock Price Plunge: On November 3, 2025, uniQure's stock price plummeted by $33.40, or over 49%, from $67.69 on October 31 to $34.29, following FDA's negative stance on its drug AMT-130's approval prospects.
- Investor Rights: KSF law firm urges investors wishing to serve as lead plaintiffs to petition the court before the deadline to protect their rights to recover economic losses.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Lawsuit Disclosure: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against uniQure N.V. on behalf of investors who purchased shares between September 24 and October 31, 2025, highlighting significant investor concerns regarding the company's transparency.
- Stock Price Plunge: On November 3, 2025, uniQure revealed that the FDA no longer viewed the data from its AMT-130 BLA submission favorably, causing the stock price to plummet from $67.69 to $34.29, a drop of over 49%, reflecting market disappointment in the company's future prospects.
- Clinical Trial Issues: The lawsuit alleges that uniQure misled investors regarding the approval status of its AMT-130 clinical trials, indicating significant deficiencies in the company's disclosure practices that misled investors.
- Investor Action Recommendation: Affected uniQure investors may seek to be appointed as lead plaintiffs in the class action by April 13, 2026, indicating that the legal risks faced by the company could impact its future financing and market trust.
See More
uniQure Faces Class Action Lawsuit Amid Stock Plunge
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against uniQure N.V., alleging securities fraud by the company and certain executives, with investors needing to apply as Lead Plaintiff by April 13, 2026, highlighting serious governance concerns.
- FDA Feedback Impact: On November 3, 2025, uniQure announced a significant shift in FDA's stance regarding its AMT-130 gene therapy BLA submission, indicating that prior clinical data may not suffice, which poses regulatory challenges for the company.
- Stock Price Plunge: Following the negative FDA feedback, uniQure's stock price plummeted by $33.40, or 49.34%, closing at $34.29 on November 3, 2025, reflecting market pessimism regarding the company's future prospects.
- Severe Legal Consequences: The class action lawsuit and stock decline may expose uniQure to substantial liability, further impacting its ability to raise funds and eroding market trust, potentially hindering future R&D initiatives.
See More
uniQure Faces Investor Lawsuit Reminder
- Lawsuit Progress Reminder: Hagens Berman updates its investigation into uniQure N.V., reminding investors to submit applications to be Lead Plaintiff by April 13, 2026, related to the securities class action for shares purchased between September 24 and October 31, 2025.
- FDA Allegations: Reports from March 5 and 6, 2026, reveal FDA officials labeled uniQure's gene therapy candidate AMT-130 as a 'failed therapy,' accusing the company of making 'distorted or manipulated comparisons' in its interactions with the FDA, which could negatively impact the company's reputation and stock price.
- Details of Allegations: The securities class action, Scocco v. uniQure N.V., alleges that throughout the Class Period, uniQure failed to disclose its interactions with the FDA and used a pivotal study design that was not approved, potentially leading investors to misjudge the company's prospects.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to utilize the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery, potentially leading to more disclosures that could influence the case's outcome.
See More
uniQure Faces Severe FDA Rebuke Amid Class Action Lawsuit
- FDA Rebuke: An FDA official publicly labeled uniQure's lead gene therapy candidate AMT-130 as a 'failed therapy,' accusing the company of conducting a 'distorted or manipulated comparison' in clinical studies, which could undermine investor confidence in the company's future prospects.
- Surgery Requirement Controversy: The FDA dismissed uniQure's ethical concerns regarding sham surgeries, clarifying that it did not request 'drilling holes' but rather 'one to three nicks in the scalp' under minimal anesthesia, potentially impacting the design and execution of the company's clinical trials.
- Legal Action Update: The securities class action against uniQure alleges that the company failed to disclose that the FDA had not approved the use of the ENROLL-HD external historical data set as a primary control for AMT-130, a lack of disclosure that may have led to significant investor losses when the stock price fell.
- Critical Deadline: Investors must apply to be Lead Plaintiff by April 13, 2026, or risk losing the opportunity to seek compensation in the lawsuit, heightening the urgency for affected shareholders to act promptly.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: uniQure N.V. (NASDAQ: QURE) is facing a class action lawsuit for securities fraud, alleging significant misstatements and omissions regarding its Huntington's disease gene therapy drug during the class period from September 24 to October 31, 2025, potentially leading to substantial investor losses.
- Stock Price Plunge: Following the revelation on November 3, 2025, that the FDA no longer accepted the data from uniQure's AMT-130 drug for BLA submission, the stock price plummeted by $33.40, or over 49%, from a closing price of $67.69 on October 31 to $34.29, severely impacting investor confidence.
- Investor Action: Affected investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP by April 13, 2026, to seek lead plaintiff status in the class action, highlighting investor concerns regarding corporate governance and transparency.
- Law Firm Background: Kessler Topaz Meltzer & Check, LLP is a leading law firm specializing in securities fraud class actions, having recovered over $25 billion for clients and represented major institutional investors, showcasing its significant influence and expertise in the securities litigation field.
See More
uniQure Faces Securities Class Action Lawsuit
- Lawsuit Deadline: Investors must file lead plaintiff applications by April 13, 2026, to participate in the securities class action against uniQure N.V. if they purchased shares between September 24 and October 31, 2025.
- Legal Allegations: uniQure and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which resulted in significant investor losses.
- Stock Price Plunge: On November 3, 2025, uniQure's stock price plummeted by $33.40, or over 49%, from $67.69 on October 31 to $34.29, following FDA's negative stance on its drug AMT-130's approval prospects.
- Investor Rights: KSF law firm urges investors wishing to serve as lead plaintiffs to petition the court before the deadline to protect their rights to recover economic losses.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Lawsuit Disclosure: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against uniQure N.V. on behalf of investors who purchased shares between September 24 and October 31, 2025, highlighting significant investor concerns regarding the company's transparency.
- Stock Price Plunge: On November 3, 2025, uniQure revealed that the FDA no longer viewed the data from its AMT-130 BLA submission favorably, causing the stock price to plummet from $67.69 to $34.29, a drop of over 49%, reflecting market disappointment in the company's future prospects.
- Clinical Trial Issues: The lawsuit alleges that uniQure misled investors regarding the approval status of its AMT-130 clinical trials, indicating significant deficiencies in the company's disclosure practices that misled investors.
- Investor Action Recommendation: Affected uniQure investors may seek to be appointed as lead plaintiffs in the class action by April 13, 2026, indicating that the legal risks faced by the company could impact its future financing and market trust.
See More
uniQure Faces Class Action Lawsuit Amid Stock Plunge
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against uniQure N.V., alleging securities fraud by the company and certain executives, with investors needing to apply as Lead Plaintiff by April 13, 2026, highlighting serious governance concerns.
- FDA Feedback Impact: On November 3, 2025, uniQure announced a significant shift in FDA's stance regarding its AMT-130 gene therapy BLA submission, indicating that prior clinical data may not suffice, which poses regulatory challenges for the company.
- Stock Price Plunge: Following the negative FDA feedback, uniQure's stock price plummeted by $33.40, or 49.34%, closing at $34.29 on November 3, 2025, reflecting market pessimism regarding the company's future prospects.
- Severe Legal Consequences: The class action lawsuit and stock decline may expose uniQure to substantial liability, further impacting its ability to raise funds and eroding market trust, potentially hindering future R&D initiatives.
See More
uniQure Faces Investor Lawsuit Reminder
- Lawsuit Progress Reminder: Hagens Berman updates its investigation into uniQure N.V., reminding investors to submit applications to be Lead Plaintiff by April 13, 2026, related to the securities class action for shares purchased between September 24 and October 31, 2025.
- FDA Allegations: Reports from March 5 and 6, 2026, reveal FDA officials labeled uniQure's gene therapy candidate AMT-130 as a 'failed therapy,' accusing the company of making 'distorted or manipulated comparisons' in its interactions with the FDA, which could negatively impact the company's reputation and stock price.
- Details of Allegations: The securities class action, Scocco v. uniQure N.V., alleges that throughout the Class Period, uniQure failed to disclose its interactions with the FDA and used a pivotal study design that was not approved, potentially leading investors to misjudge the company's prospects.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to utilize the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery, potentially leading to more disclosures that could influence the case's outcome.
See More
